<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>CStone Pharmaceuticals ( (HK:2616) ) just unveiled an update. CStone Pharmaceuticals has begun nationwide commercial supply of its first domestically manufactured batch of 100 mg pralsetinib capsules in China, marking a key step in localizing the supply chain for this targeted cancer therapy. The company emphasized that the locally produced version matches imported standards in quality and efficacy, supported by rigorous technical transfers and process validation. Following pralsetinib’s inclusion in China’s National Reimbursement Drug List at the start of 2026, patient access has expanded and in-market sales volume has climbed by over 430% year-on-year as of April 2026. Leveraging this surge, CStone expects pralsetinib sales to surpass RMB 300 million in 2026, while the new domestic supply chain is intended to meet rising clinical demand, improve cost efficiency, and bolster margins for stakeholders in the oncology market. Pralsetinib is a once-daily oral targeted therapy approved in mainland China for several RET fusion-positive non-small cell lung cancer and thyroid cancer indications. The drug also holds approvals in Hong Kong and Taiwan for RET fusion-positive NSCLC and thyroid cancer, underscoring CStone’s regional footprint in precision oncology treatments. More about CStone Pharmaceuticals CStone Pharmaceuticals is a China-focused biopharmaceutical company specializing in innovative oncology therapies. The group develops and commercializes targeted cancer drugs, with a growing portfolio addressing advanced solid tumors and a strategic focus on the Chinese and greater Asia markets. Average Trading Volume: 14,771,549 Technical Sentiment Signal: Buy Current Market Cap: HK$13.31B </div>

02616

510660

516500

CStone Pharmaceuticals has launched nationwide supply of its domestically produced pralsetinib capsules in China, enhancing local supply chain for this cancer therapy. The drug's sales surged over 430% year-on-year, with expectations to exceed RMB 300 million in 2026. This move aims to meet rising clinical demand and improve cost efficiency. Pralsetinib is approved for RET fusion-positive non-small cell lung cancer and thyroid cancer, reinforcing CStone's position in precision oncology in the region.

Tip Ranks

CSTONE PHARMA-B

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

Penghua SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge